Northern Trust’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-128,892
| Closed | -$753K | – | 4662 |
|
|
2022
Q4 | $753K | Sell |
128,892
-442
| -0.3% | -$2.32K | ﹤0.01% | 3363 |
|
|
2022
Q3 | $866K | Buy |
129,334
+32,099
| +33% | +$195K | ﹤0.01% | 3345 |
|
|
2022
Q2 | $410K | Sell |
97,235
-1,997
| -2% | -$7.9K | ﹤0.01% | 3607 |
|
|
2022
Q1 | $334K | Sell |
99,232
-1,326
| -1% | -$4.2K | ﹤0.01% | 3900 |
|
|
2021
Q4 | $317K | Sell |
100,558
-4,622
| -4% | -$15.4K | ﹤0.01% | 4000 |
|
|
2021
Q3 | $344K | Sell |
105,180
-6,660
| -6% | -$23.3K | ﹤0.01% | 3915 |
|
|
2021
Q2 | $473K | Sell |
111,840
-225,772
| -67% | -$956K | ﹤0.01% | 3732 |
|
|
2021
Q1 | $1.68M | Sell |
337,612
-57,485
| -15% | -$465K | ﹤0.01% | 3332 |
|
|
2020
Q4 | $4.99M | Sell |
395,097
-10,846
| -3% | -$124K | ﹤0.01% | 2685 |
|
|
2020
Q3 | $3.99M | Sell |
405,943
-6,864
| -2% | -$67.6K | ﹤0.01% | 2676 |
|
|
2020
Q2 | $4.11M | Buy |
412,807
+78,378
| +23% | +$752K | ﹤0.01% | 2636 |
|
|
2020
Q1 | $2.96M | Buy |
334,429
+51,128
| +18% | +$504K | ﹤0.01% | 2627 |
|
|
2019
Q4 | $2.61M | Sell |
283,301
-19,213
| -6% | -$136K | ﹤0.01% | 2959 |
|
|
2019
Q3 | $1.78M | Buy |
302,514
+6,758
| +2% | +$71.7K | ﹤0.01% | 3163 |
|
|
2019
Q2 | $3.55M | Buy |
295,756
+4,685
| +2% | +$50.4K | ﹤0.01% | 2743 |
|
|
2019
Q1 | $3.51M | Buy |
291,071
+150
| +0.1% | +$2.21K | ﹤0.01% | 2761 |
|
|
2018
Q4 | $3.65M | Sell |
290,921
-187,269
| -39% | -$2.59M | ﹤0.01% | 2702 |
|
|
2018
Q3 | $7.1M | Sell |
478,190
-195,276
| -29% | -$3.07M | ﹤0.01% | 2469 |
|
|
2018
Q2 | $11.3M | Buy |
673,466
+37,369
| +6% | +$726K | ﹤0.01% | 2187 |
|
|
2018
Q1 | $14.6M | Buy |
636,097
+199,090
| +46% | +$4.43M | ﹤0.01% | 1922 |
|
|
2017
Q4 | $11.3M | Buy |
437,007
+203,806
| +87% | +$4.1M | ﹤0.01% | 2112 |
|
|
2017
Q3 | $3.44M | Sell |
233,201
-10,788
| -4% | -$157K | ﹤0.01% | 2864 |
|
|
2017
Q2 | $3.4M | Buy |
243,989
+24,622
| +11% | +$363K | ﹤0.01% | 2855 |
|
|
2017
Q1 | $3.74M | Buy |
219,367
+523
| +0.2% | +$6.27K | ﹤0.01% | 2731 |
|
|
2016
Q4 | $2.25M | Buy |
218,844
+7,921
| +4% | +$72.4K | ﹤0.01% | 3022 |
|
|
2016
Q3 | $2.13M | Buy |
210,923
+1,169
| +0.6% | +$12.8K | ﹤0.01% | 3042 |
|
|
2016
Q2 | $2.36M | Sell |
209,754
-28,371
| -12% | -$361K | ﹤0.01% | 2939 |
|
|
2016
Q1 | $3.25M | Buy |
238,125
+51,738
| +28% | +$745K | ﹤0.01% | 2692 |
|
|
2015
Q4 | $3.54M | Buy |
186,387
+7,700
| +4% | +$167K | ﹤0.01% | 2687 |
|
|
2015
Q3 | $3.35M | Buy |
178,687
+129,622
| +264% | +$2.2M | ﹤0.01% | 2720 |
|
|
2015
Q2 | $731K | Buy |
49,065
+29,599
| +152% | +$451K | ﹤0.01% | 3442 |
|
|
2015
Q1 | $295K | Buy |
19,466
+7,594
| +64% | +$106K | ﹤0.01% | 3760 |
|
|
2014
Q4 | $158K | Hold |
11,872
| – | – | ﹤0.01% | 3876 |
|
|
2014
Q3 | $150K | Sell |
11,872
-52,370
| -82% | -$508K | ﹤0.01% | 3925 |
|
|
2014
Q2 | $648K | Buy |
64,242
+37,841
| +143% | +$365K | ﹤0.01% | 3527 |
|
|
2014
Q1 | $355K | Buy |
+26,401
| New | +$373K | ﹤0.01% | 3638 |
|
Northern Trust's CNCE Position: Q1 2023 in Review
Northern Trust sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 128,892 shares — an estimated $753K sold.
Northern Trust first reported a position in CNCE in Q1 2014 and held it in 36 quarters. The position peaked at $14.6M in Q1 2018. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Northern Trust reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Northern Trust sold 128,892 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $753K.
- Northern Trust first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 36 quarters.
- Northern Trust's Concert Pharmaceuticals, Inc. position peaked at $14.6M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Northern Trust's 13F filing for Q1 2023, filed 15 May 2023.